Last updated on August 2020

Study of Safety Efficacy and Tolerability of Secukinumab Versus Placebo in Combination With SoC Therapy in Patients With Active Lupus Nephritis

Brief description of study

The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features).

Clinical Study Identifier: NCT04181762

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.